Active ingredientAcoramidisCat. No. P-A033-001CAS 1446711-81-4Family · Pharmaceutical analytical standards
Acoramidis
An oral transthyretin stabiliser, approved in the United States in 2024 and in the European Union in 2025 for transthyretin amyloid cardiomyopathy (ATTR-CM) in adults: it stops the protein from breaking apart and forming amyloid deposits. This family brings together the active ingredient.
Did you know?It was designed to mimic a natural protective variant of transthyretin called T119M. During development it was called AG10, that is Alhamadsheh-Graef molecule 10, after the surnames of its creators.
Go to the active ingredient →Active ingredientAcoramidisCat. No. P-A033-001CAS 1446711-81-4No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.